Altruist Biologics

What Altruist Biologics does

Altruist Biologics is a contract development and manufacturing organization (CDMO) established in 2022 as a wholly-owned subsidiary of Innovent Biologics (HKEX: 01801), providing fully integrated biologics development and manufacturing services to pharmaceutical and biotechnology companies. The company serves clients developing monoclonal antibodies, bispecific and multispecific antibodies, fusion proteins, recombinant proteins, and antibody-drug conjugates (ADCs), spanning from cell line development through commercial-scale GMP manufacturing and regulatory support. It operates two manufacturing facilities in China — Suzhou with 60,000 liters of capacity and Hangzhou with a projected 172,000 liters including four 20,000-liter stainless steel bioreactors (the first and largest of their kind in China) — for a combined planned capacity of 232,000 liters by 2026. The company has manufactured over 2,000 batches with a success rate exceeding 99.8%, passed 30+ regulatory inspections from FDA, EMA, PMDA, and NMPA, and supported 70+ IND projects and 18 BLAs/NDAs/MAAs.

The company's core technology platforms include Altru-CON (high-concentration formulation up to 200 mg/mL), AltruCHOice (proprietary CHO-K1 cell line achieving 13g/L titers in 10 weeks from DNA to Primary Cell Bank), and AltruDARX (flexible drug-to-antibody ratio bioconjugation). ADC manufacturing capabilities include high-containment production with an Occupational Exposure Limit of 5 ng/m³. Revenue is generated through professional services fees for development, project-based contracts, and long-term manufacturing agreements, with pricing custom-quoted based on project scope, scale (1,000L to 20,000L), and modality. A notable strategic partnership with LongBio is valued at over 500 million CNY for NDA and commercial production of two molecules. The company is led by Dr. Kaisong Zhou, who also serves as COO of parent Innovent Biologics, with a leadership team drawn from Genentech, GSK, Novartis, Pfizer, Bristol-Myers Squibb, and the U.S. FDA.

Name

Altruist Biologics

Legal name

Altruist Biotechnology (Hangzhou) Co., Ltd.

Website

https://altruistbio.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Biologics Contract Development and Manufacturing (CDMO)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Biologic API/Drug Substance Manufacturing Services (HLAAAKAA)

Keywords

• Biologics contract manufacturing
• Antibody drug conjugates
• Cell line development
• GMP drug substance
• Biologics CDMO services

Headquarters

HQ city

Suzhou

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. CDMO Manufacturing Services: Contract development and manufacturing organization providing end-to-end biologics development and manufacturing services. Revenue generated through service fees for cell line development, process development, GMP manufacturing, regulatory support, and quality assurance services. Services billed through project-based contracts and long-term manufacturing agreements.
2. Strategic Partnership Manufacturing: Long-term strategic manufacturing partnerships with biotech companies for NDA application and commercial production. Partnership with LongBio valued at over 500 million CNY for development and commercial production services.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Altruist Biologics is a global contract development and manufacturing organization (CDMO) providing fully integrated biologics services spanning cell line development, process and formulation development, analytical method development, bioconjugate (ADC) development and manufacturing, GMP drug substance and drug product manufacturing at 1,000L to 20,000L scales, labeling and packaging, and CMC regulatory support for pharmaceutical and biotech clients in the US, Europe, and China. The company leverages proprietary platforms (Altru-CON™, AltruCHOice, AltruDARX) and high-containment ADC manufacturing infrastructure at GMP-certified facilities in Suzhou and Hangzhou.

Product overview

Altruist Biologics is a contract development and manufacturing organization (CDMO) offering a fully integrated platform of biologics services spanning from molecule to market. The core offering comprises four interconnected service pillars: Mammalian Cell Culture Services (including Cell Line Development, Process Development, Formulation Development, and Analytical Method Development), Bioconjugates/ADCs (with platforms like AltruDARX Flexible DAR), Manufacturing Services (GMP Drug Substance and Drug Product manufacturing including aseptic fill-finish and labeling/packaging), and Regulatory Support. Supporting technology platforms include Altru-CON™ for high-concentration formulations and AltruCHOice proprietary cell lines. The company operates two GMP manufacturing facilities in Suzhou (60,000L capacity) and Hangzhou (172,000L total capacity with four 20,000L bioreactors).

Differentiator

Problem solved

Functional benefit

Brands

• Altru-CON™: High-concentration formulation technology platform enabling protein concentrations up to 200 mg/mL with over two-fold viscosity reduction for subcutaneous administration.
• AltruCHOice
• AltruDARX

Products and services

• Mammalian Cell Culture Services Comprehensive mammalian cell culture services for biologics from cell line development through clinical and commercial manufacturing, covering monoclonal antibodies, bispecific/multispecific antibodies, fusion proteins, and recombinant proteins.
• Bioconjugates (ADC) Development and Manufacturing End-to-end development and manufacturing services for antibody-drug conjugates (ADCs) and other novel bioconjugates, spanning from linker-payload intermediates to final bioconjugate drug substance and drug product for clinical and commercial supply.
• GMP Drug Substance Manufacturing Clinical- and commercial-scale GMP drug substance manufacturing with bioreactor capacity from 1,000 L to 20,000 L, including both single-use and stainless steel options at Suzhou and Hangzhou facilities.
• GMP Drug Product Manufacturing Aseptic fill-finish GMP manufacturing including vial filling (2-50R), pre-filled syringes (0.5-2.25ml), auto-injector assembly, and lyophilization using automated, isolator-based formulation and filling systems.
• Labeling & Packaging Clinical labeling, secondary packaging, cold chain transportation, storage, and global logistics and distribution services for finished biologics.
• Regulatory Support CMC advisory services, regulatory submission support, registration and inspection support, and regulatory intelligence monitoring for IND, IMPD, DSUR, NDA, BLA, and PAC submissions across US, Europe, China, and other major markets.

Quantifiable outcome

• Batch success rate >99.8% and 2,000+ batches manufactured in China
• +6 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• LongBiomajorStrategic or Co-development Partner · 26 July 2023Strategic partnership for NDA application and commercial production for two molecules in LongBio's pipeline. Total cooperation amount exceeds 500 million CNY. Altruist provides comprehensive experience in NDA applications, quality systems compliant with international standards, and sustainable commercial manufacturing capability to help LongBio accelerate NDA process in China and global market, as well as provide commercial manufacturing after market launch.

Scale indicators13 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Genscript ProBio: GenScript ProBio is a China-based biologics CDMO offering cell line development, process development, GMP manufacturing, and analytical services for mAbs, bispecifics, ADCs, and gene therapies. Directly comparable to Altruist in scope and shared Chinese CDMO competitive landscape with overlapping global biotech and pharma client base.
• Samsung Biologics: Samsung Biologics operates some of the world's largest single-site mammalian cell culture CDMO capacity (>600,000L) and serves global pharma clients with mAb and ADC manufacturing. Comparable to Altruist in product offerings (large-scale biologics manufacturing) but differentiated by greater scale, broader modality coverage, and Korea-based geography with established Western client base.
• WuXi Biologics: WuXi Biologics is the largest China-based biologics CDMO, offering end-to-end mAb, bispecific, and ADC development and manufacturing from cell line development through commercial supply. It is the most direct competitor to Altruist given overlapping modalities (mAbs, ADCs), integrated CMC services, and shared customer segment across global pharma and biotech.
• Lonza Biologics: Lonza is one of the largest global mammalian and microbial biologics CDMOs with extensive mammalian cell culture, ADC, and fill-finish capabilities across multiple continents. Directly comparable to Altruist in serving global pharma and biotech clients seeking integrated biologics manufacturing from clinical to commercial scale.
• AGC Biologics: AGC Biologics is a global CDMO providing mammalian and microbial biologics manufacturing services for mAbs, recombinant proteins, and gene therapies. Comparable to Altruist in mammalian cell culture biologics CDMO offerings, integrated CMC services, and global regulatory support for clinical and commercial supply.
• Pharmaron Biologics: Pharmaron Biologics is the biologics CDMO arm of Pharmaron, providing cell line development, process development, and GMP manufacturing for mAbs, recombinant proteins, and ADCs from facilities in China and the US. Comparable to Altruist in integrated biologics CDMO services, ADC capabilities, and end-to-end CMC offerings from DNA to commercial.

Others

• MilliporeSigma (BioReliance CDMO Services): MilliporeSigma, the life science arm of Merck KGaA, provides biopharmaceutical contract testing, development, and manufacturing services. Comparable as a complementary ecosystem participant providing services adjacent to biologics CDMO workflows (testing, process development, viral clearance) but not a direct competitor for full-scale biologics manufacturing.

Regional players

• WuXi STA: WuXi STA is the small-molecule API and drug product CDMO arm of WuXi AppTec, focused on API development and manufacturing. While small-molecule focused rather than biologics, it is comparable as a sibling WuXi CDMO operating from China serving global pharma clients with similar end-to-end development-to-commercial service model.

Broad incumbents

• Catalent (Novo Holdings): Catalent is a global CDMO with significant biologics and fill-finish capabilities serving pharma and biotech across multiple dosage forms. Comparable to Altruist in biologics drug substance manufacturing and drug product fill-finish for mAb and biologic clients, though it offers a broader portfolio across multiple modalities.
• Boehringer Ingelheim BioXcellence: Boehringer Ingelheim BioXcellence is the biopharmaceutical contract manufacturing arm of Boehringer Ingelheim, offering mammalian cell-based biologics CDMO services including mAbs, fusion proteins, and expression technologies. Comparable to Altruist in integrated biologics CDMO services with global regulatory expertise and ADC capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights8 records

Customer concentration

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Altruist Biologics